Warum Bitcoin als Wertspeicher in keinem diversifizierten Portfolio fehlen sollte. Jetzt lesen -w-
08.12.2014 22:05:26

Prothena to Present at the Oppenheimer 25th Annual Healthcare Conference in New York

DUBLIN, Dec. 8, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve amyloid or cell adhesion, announced that Tran Nguyen, the Company's Chief Financial Officer, will be presenting at the Oppenheimer 25th Annual Healthcare Conference on Thursday, December 11, 2014, at 10:55 AM EST. The conference will be held at the Crowne Plaza Hotel in New York.

A live webcast of the presentation can be accessed through the investor relations section of the Company's website at www.prothena.com. Following the live presentation, a reply of the webcast will be available on the Company's website for 90 days.

About Prothena

Prothena Corporation plc is a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve amyloid or cell adhesion. The Company focuses on therapeutic monoclonal antibodies directed specifically to disease-causing proteins and its antibody-based product candidates target a number of potential indications including AL and AA forms of amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002) and novel cell adhesion targets involved in psoriasis and other inflammatory diseases (PRX003).

For more information, please visit the Company's web site at www.prothena.com.
CONTACT: Investors:  Tran Nguyen, CFO
         650-837-8535, IR@prothena.com
         
         Media:  Angela Bitting
         925-202-6211, angela.bitting@prothena.com



This announcement is distributed by Nasdaq OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Prothena Corporation via Globenewswire

HUG#1878364

Analysen zu Prothena Corporation PLCmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Prothena Corporation PLC 14,90 4,20% Prothena Corporation PLC